Spero Therapeutics Inc Stock, NASDAQ:SPRO
675 Massachusetts Avenue, 14th floor, Cambridge, Massachusetts 02139
United States of America
Number of Employees: 89
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.